CSL Limited presented its fiscal year 2026 full-year results on August 18, 2026, describing the period as a 'reset year' with significant non-cash charges. The company reported a statutory net loss of $2.6 billion, driven by $7.1 billion in impairments and restructuring costs. Despite this, underlying operations remained profitable and cash generative. Interim CEO Gordon Naylor emphasized that the company has been 'positioned to return to sustainable growth' following operational simplification and a comprehensive transformation program.
Financial Performance
The company generated $15.8 billion in revenue, representing a 1% decline at constant currency, while underlying NPATA fell 2% to $3.1 billion. Revenue declined modestly across the group, with CSL Behring down 1% to $11.4 billion and CSL Seqirus down 8% to $2.0 billion.
Business Segments
CSL Behring, the company’s largest division, faced a challenging year but showed signs of stabilization in the second half. The immunoglobulin franchise generated $6.2 billion in revenue, flat year-over-year but showing improvement with second-half growth of 7%. CSL Vifor’s performance reflected both near-term strength and significant future headwinds, with nephrology dialysis revenue surging 18% to $1.0 billion.
Outlook
The company expects modest improvement in gross profit margin in FY27 and has delivered tangible results from its strategic transformation program, exceeding initial cost savings targets. CSL completed an A$1 billion share buyback during the year and maintained its dividend at $2.92 per share, signaling confidence in the balance sheet and future prospects.